Bisphosphonate therapy and osteonecrosis of the jaw

Many prostate cancer patients are advised to use bisphosphonate therapy to prevent bone loss and other bone-related adverse events associated with long-term hormonal therapy. A disorder now known as bisphosphonate-related osteonecrosis of the jaw (BRONJ) was initially associated with bisphosphonate therapy in 2003-04 and there has been extensive research on this relationship since that date. … READ MORE …

Furore about Fosamax

There has been a lot of media noise in the past few days about two studies suggesting that a drug called alendronate (Fosamax/Merck) may be associated with a significant risk for osteonecrosis of the jaw (ONJ). … READ MORE …

The weekend prostate cancer news: November 8, 2008

This weekend’s prostate cancer news includes information about:

  • The evolving role of 3.0 T and 1.5 T endorectal MRI in prostate cancer diagnosis
  • The role of bone scans in diagnosis of men with PSA levels below and above 20 ng/ml
  • A potential radio-sensitizer that may improve outcomes following radiotherapy
  • A side effect of abiraterone acetate, and its management
  • Bisphosphonate therapy and osteonecrosis of the jaw or ONJ … READ MORE …